Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients

LC Martial, BAW Jacobs, EAM Cornelissen, AFJ de Haan, Birgit Koch, DM Burger, RE Aarnoutse, MF (Michiel) Schreuder, RJM Bruggemann

Research output: Contribution to journalArticleAcademic

13 Citations (Scopus)


MPA is an immunosuppressive agent used to prevent graft rejection after renal transplantation. MPA shows considerable inter- and intraindividual variability in exposure in children and has a defined therapeutic window, and TDM is applied to individualize therapy. We aimed to study the exposure to MPA measured as the AUC in pediatric renal transplant patients, to identify factors influencing exposure and to assess target attainment. Children transplanted between 1998 and 2014 in a single center were included. Two groups were identified: Group 1 (AUC <3 wk post-transplantation) and Group 2 (AUC >18 months post-transplantation). Therapeutic targets were set at: AUC(0-12h) of 30-60 mg h/L. A total of 39 children were included in Group 1 (median age 13.3 yr) vs. 14 in Group 2 (median age 13.4 yr). AUC(0-12h) was 29.7 mg h/L in Group 1 and 56.6 mg h/L in Group 2, despite a lower dosage in Group 2 (584 and 426 mg/m(2), respectively). About 46% of patients reached the target AUC(0-12h) in Group 1. Time since transplantation and serum creatinine were significantly associated with MPA exposure (p < 0.001), explaining 36% of the variability. Individualization of the mycophenolate dose by more intense and more early TDM could improve target attainment.
Original languageUndefined/Unknown
Pages (from-to)492-499
Number of pages8
JournalPediatric Transplantation
Issue number4
Publication statusPublished - 2016

Cite this